Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma-Reference-Cited by-同舟云学术

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

Published:2013-11-18 Issue:5 Volume:120 Page:692-701
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Grivas Petros D.¹,Daignault Stephanie²,Tagawa Scott T.³,Nanus David M.³,Stadler Walter M.⁴,Dreicer Robert⁵,Kohli Manish⁶,Petrylak Daniel P.⁷,Vaughn David J.⁸,Bylow Kathryn A.⁹,Wong Steven G.¹⁰,Sottnik Joseph L.¹¹,Keller Evan T.¹²,Al-Hawary Mahmoud¹³,Smith David C.¹,Hussain Maha¹

Affiliation:

1. Department of Internal Medicine; University of Michigan Comprehensive Cancer Center; Ann Arbor Michigan

2. Biostatistics Department; University of Michigan Comprehensive Cancer Center; Ann Arbor, Michigan

3. Departments of Medicine and Urology; Weill Cornell Medical College; New York

4. Department of Medicine; The University of Chicago; Chicago Illinois

5. Department of Solid Tumor Oncology; Cleveland Clinic; Cleveland Ohio

6. Department of Oncology; Mayo Clinic; Rochester Minnesota

7. Departments of Medical Oncology and Urology; Yale University Cancer Center; New Haven Connecticut

8. Department of Medicine; University of Pennsylvania Abramson Cancer Center; Philadelphia Pennsylvania

9. Department of Medicine; Medical College of Wisconsin; Milwaukee Wisconsin

10. Department of Medicine; University of California at Los Angeles School of Medicine; Los Angeles California

11. Department of Urology; University of Michigan Comprehensive Cancer Center; Ann Arbor Michigan

12. Departments of Urology and Pathology; University of Michigan Comprehensive Cancer Center; Ann Arbor Michigan

13. Department of Radiology; University of Michigan Comprehensive Cancer Center; Ann Arbor Michigan

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28477/fullpdf

Reference33 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. First- and second-line therapy for metastatic urothelial carcinoma of the bladder;Yafi;Curr Oncol,2011

3. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;Maase;J Clin Oncol,2005

4. The biology of VEGF and its receptors;Ferrara;Nat Med,2003

5. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas;Dickinson;Br J Urol,1994

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in Metastatic Urothelial Carcinoma;Oncology;2024-07-17

2. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution;International Journal of Clinical Oncology;2024-06-08

3. Precision medicine for urothelial carcinoma: An international perspective;Urologic Oncology: Seminars and Original Investigations;2024-01

4. Progress in systemic therapy for advanced-stage urothelial carcinoma;Nature Reviews Clinical Oncology;2023-11-09

5. The prognostic efficacy of a sustainable geriatric nutritional risk index for avelumab switch maintenance therapy in metastatic urothelial carcinoma;2023-11-07